Related Experiment Videos
[Antiganglioside antibodies: when, which and for what]
E Gallardo1, R Rojas-García, R Belvís
1Servicio de Neurología. Hospital de la Santa Creu i Sant Pau. Barcelona.
Neurologia (Barcelona, Spain)
|August 4, 2001
Summary
Specific antiganglioside antibodies are clinically useful biomarkers for diagnosing neuropathies like Miller-Fisher syndrome and multifocal motor neuropathy. Detecting anti-GQ1b, anti-GD1a, and IgM anti-GM1 antibodies aids in diagnosis and prognosis.
Area of Science:
- Neuroimmunology
- Clinical Neurology
- Immunoserology
Context:
- Antiganglioside antibodies are implicated in various neurological disorders.
- Understanding specific antibody-neuropathy correlations is crucial for diagnosis and management.
Purpose:
- To investigate the clinical utility of antiganglioside antibodies in differentiating neurological syndromes.
- To establish associations between specific antibodies and clinical presentations.
Summary:
- Analysis of 275 sera revealed high prevalence of anti-GQ1b in Miller-Fisher syndrome (MFS) (97.3%).
- Guillain-Barré syndrome (GBS) showed various antiganglioside specificities, with anti-GD1a indicating axonal damage.
- IgM anti-GM1 antibodies were predominantly found in multifocal motor neuropathy (MMN).
Impact:
- Anti-GQ1b antibody detection confirms MFS diagnosis.
- Anti-GD1a antibodies suggest axonal damage in GBS, potentially indicating a worse prognosis.
- IgM anti-GM1 antibodies are specific to MMN, aiding differential diagnosis.